These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21651645)

  • 1. KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
    Kamiya K; Watanabe M; Kohno M; Izumi Y; Horinouchi H; Kawamura M; Shimada N; Nomori H
    Respirology; 2011 Aug; 16(6):976-82. PubMed ID: 21651645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
    Qin HF; Qu LL; Liu H; Wang SS; Gao HJ
    Asian Pac J Cancer Prev; 2013; 14(7):4205-8. PubMed ID: 23991977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
    Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
    Fujiwara Y; Kiura K; Toyooka S; Hotta K; Tabata M; Takigawa N; Soh J; Tanimoto Y; Kanehiro A; Kato K; Date H; Tanimoto M
    Lung Cancer; 2008 Jan; 59(1):81-7. PubMed ID: 17765355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
    Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
    Okamoto T; Nakamura T; Ikeda J; Maruyama R; Shoji F; Miyake T; Wataya H; Ichinose Y
    Eur J Cancer; 2005 Jun; 41(9):1286-90. PubMed ID: 15939264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
    Zhuang J; Tang X; Du Z; Yang M; Zhou Y
    Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
    Ohara G; Kurishima K; Ishikawa H; Satoh H; Hizawa N
    Lung Cancer; 2008 Jan; 59(1):138; author reply 139. PubMed ID: 18006181
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
    Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
    Xu CA; Su H; Liu JL; Li L; Zou HW
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
    Ishikawa N; Daigo Y; Takano A; Taniwaki M; Kato T; Hayama S; Murakami H; Takeshima Y; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Cancer Res; 2005 Oct; 65(20):9176-84. PubMed ID: 16230376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer.
    Tanaka S; Hattori N; Ishikawa N; Shoda H; Takano A; Nishino R; Okada M; Arihiro K; Inai K; Hamada H; Yokoyama A; Kohno N
    Int J Cancer; 2012 Jan; 130(2):377-87. PubMed ID: 21351094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
    Chiu CH; Shih YN; Tsai CM; Liou JL; Chen YM; Perng RP
    Lung Cancer; 2007 Aug; 57(2):213-21. PubMed ID: 17449138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of early serial change in serum carcinoembryonic antigen levels as a predictive marker for radiological response to gefitinib in Japanese patients with non-small cell lung cancer.
    Hotta K; Kiura K; Tabata M; Takigawa N; Fujiwara Y; Umemura S; Tanimoto M
    Anticancer Res; 2007; 27(3B):1737-41. PubMed ID: 17595807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
    Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
    Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
    Gu AQ; Wang HM; Shi CL; Xiong LW; Gao ZQ; Han BH
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):71-4. PubMed ID: 20211075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.